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Abstract 
 
Purpose: Multi-parametric MRI (mpMRI) may identify radio-recurrent intra-prostatic 
cancer accurately. We aimed to compare visually directed MRI-targeted biopsies 
(MRI-TB) to an accurate reference standard – Transperineal Prostate Mapping 
(TPM) biopsies with 5mm sampling - in the detection of clinically significant cancer in 
men with biochemical failure after radiotherapy.  
 
Methods: A retrospective registry analysis between 2006-2014 identified 77 men 
who had undergone mpMRI followed by MRI-TB and TPM. Clinical significance was 
set at two definitions of disease. Definition 1 was Gleason >/=4+3 and/or maximum 
cancer core length >/=6mm. Definition 2 was Gleason >/=3+4 and/or maximum 
cancer core length >/=4mm.  
 
Results: Of the 77 patients included, mean age was 70 years (range 61-82; SD 
5.03). Median PSA at time of EBRT was 14ng/ml (IQR 7.83-32.50). The most 
frequent EBRT dose given was 74Gy over 37 fractions. Eight patients had iodine-
seed implant brachytherapy or high-dose rate brachytherapy. Neo-adjuvant/adjuvant 
hormonal therapy use was reported in 38.  Time from EBRT to biochemical 
recurrence was a median 60 months (IQR 36.75-85.00). Median PSA at time of 
mpMRI was 4.68ng/ml (IQR 2.68-7.60). The median time between mpMRI and 
biopsy was 2.76 months (IQR 1.58-4.34). Total of 2,392 TPM and 381 MRI-TB cores 
were taken with 18% and 50% cancer detection, respectively. Detection rates of 
definition 1 clinically significant cancer were 52/77 (68%) vs. 55/77 (71%) for MRI-TB 
and TPM, respectively. MRI-TB was more efficient requiring 1 core vs. 2.8 cores to 
detect definition 2 cancer.  
 
Conclusion: MRI-TB seems to have encouraging detection rates for clinically 
significant cancer with fewer cores compared to TPM, although TPM had higher 
detection rates for smaller lower grade lesions.  
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Introduction 
 
Radiotherapy is effective in treating localised prostate cancer. However, biochemical 
failure between 7 years can occur in approximately one-third of men.1  Without 
additional therapy time for distant spread has been found to be approximately 5 
years2, so there may be a potential window of opportunity for further curative local 
salvage therapy. Despite this potential for delivering local curative therapy, most men 
who fail radiotherapy are placed on expectant management with delayed androgen 
deprivation therapy (ADT)3. This may be because the existing therapies target the 
whole prostate using salvage radical prostatectomy, cryosurgery, high intensity 
focused ultrasound or brachytherapy – and confer significant risk of incontinence and 
rectal injury.4  
 
For local salvage therapy to be delivered appropriately, an accurate determination of 
the presence or absence of localised recurrence in this group of patients is 
important. This may also aid the delivery of a focal tissue-preserving approach to 
salvage local therapy in order to mitigate the harms currently seen with whole-gland 
salvage 4. Whilst transrectal ultrasound systematic 10-12 core (TRUS)1 guided 
biopsies can be used to detect or rule-out local disease, they have inherent 
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inaccuracies as a diagnostic strategy and may lead to inappropriate therapeutic 
decisions. First, TRUS-guided biopsies can miss clinically significant disease. 
Second, they can misclassify significant disease as insignificant. These two errors 
may lead to a patient undergoing improper expectant management and ADT rather 
than potentially curative local therapy. Third, TRUS-guided biopsies detect small 
volume clinically insignificant disease that may inappropriately be attributed as the 
cause of biochemical failure, when actually micro-metastatic disease may be the 
cause of a rising PSA.5 6 This could lead to unnecessary local salvage therapy with 
the presumption that metastases are not present especially if staging scans – with 
their own inherent inaccuracies – are negative. 
 
If imaging could be used to identify recurrent intra-prostatic cancer more accurately, 
this might help in the selection of patients for local salvage therapies.7  Multi-
parametric MRI (mpMRI) using T2-weighted (T2W), Dynamic Contrast Enhanced 
(DCE-MRI) and Diffusion Weighting Imaging (DWI), has gained much interest in the 
diagnosis of prostate cancer in the primary setting.8 9 A limited number of studies 
have shown that mpMRI may have encouragingly high performance characteristics 
in the radiorecurrent setting. 10 1112 13 14  
 
We compared the cancer detection rates of biopsies targeted to an mpMRI-detected 
lesion (MRI-Target Biopsy – MRI-TB) against Transperineal Prostate Mapping (TPM) 
using a 5mm sampling frame - in men with rising PSA after prior radiotherapy. The 
use of TPM in this setting allowed us to compare the performance of targeted 
biopsies in all men who underwent mpMRI due to biochemical failure without 
selection bias. This study is START and STARD compliant.15  
 
Materials and Methods 
 
Research ethics committee exemption was granted for this study by the institutional 
research office. A retrospective analysis identified 147 consecutive men, between 
July 2006 and May 2014 referred with suspicion of radio-recurrent prostate cancer 
due to rising PSA post-EBRT or brachytherapy, a lesion suspicious for cancer on 
mpMRI and who subsequently underwent transperineal biopsies. We contacted all 
referring physicians and sent reminders in order to collate all pre-radiotherapy 
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baseline disease characteristics. All men had no evidence of distant disease based 
on a combination of radioisotope bone-scan and CT/PET scans (FDG initially and 
later 18F-choline). This is the standard of care for such patients referred to our 
institution for consideration of local salvage therapy.  Our cohort comprised of 77 
men who underwent an MRI-TB at the same time as TPM biopsies. MRI-TB was 
taken first followed by TPM. Eight men were referred having been started on ADT 
and underwent imaging whilst on hormones. Eleven men underwent biopsy whilst on 
hormonal treatment, which had been started post-imaging in 3. The mean time for 
hormonal treatment in these 11 was 8 months. Complications were assessed on 
review of subsequent clinic appointments.  
 
MR-Imaging 
The MRI scans were prospectively reported (blind to all histology). Reports were 
conducted by several expert uro-radiologists. Radiologists had access to all baseline 
clinical data including pre-radiotherapy disease characteristics and post-radiotherapy 
PSA kinetics, where available. Due to the nature of the aims of our study – to 
determine the clinical validity of MRI-targeting – there was no need for double 
reporting as the targeting was based on the report issued at the time. 
 
As discussed in our previous paper 14, each prostate was divided into four sectors in 
3 sections (base, mid-gland, apex) with the urethra as the anatomical dividing point 
between right and left and anterior and posterior. Each of the 12 resulting sectors 
and seminal vesicles were scored using the 5-point Likert scale (1 – highly likely no 
tumour and 5 – highly likely tumour).16  
 
As a retrospective study, from the period 2007-2014, scans were reported prior to 
the European Consensus report on prostate MRI and the ESUR guidelines on 
reporting of prostate MRI.16 17 However, our three senior uro-radiologists were 
formally involved in both of the guidelines and much of how we reported the scans in 
this series is currently incorporated into the ESUR and British Society of Uro-
Radiology guidelines18. Patients were scanned on the 1.5T scanner (Symphony or 
Avanto, Siemens AG, Munich, Germany) using a pelvic phased-array coil. The 
sequences were evaluated in the following manner. First, the T2 sequences were 
used to provide morphology and anatomical localisation. DCE played a greater role 
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for the peripheral zone with the additional reference of the DWI scans. A score of 1 
or 2 was given if there was no enhancement; a score of 3 given if symmetrical 
diffuse enhancement was seen; if there was focal or asymmetrical enhancement ≥3 
mm and no abnormality seen on DWI, a score of 4 was given; if there was focal or 
asymmetrical enhancement ≥3 mm and/or corresponding DWI abnormality in the 
same anatomical location, a score of 5 was recorded.  
 
A similar technique was used to report for lesions in the transition zone, with DWI 
sequences given greater weighting compared to DCE. DCE shows more 
enhancement of adenomas in this zone, especially after radiotherapy. However, an 
equivocal score of 3 based on DWI could be upgraded to 4 or 5 if there was an 
associated obvious DCE abnormality in the same anatomical location.14  
 
Biopsy strategies 
MRI-TB were carried out with cognitive targeting or as has been deemed more 
accurately, visual estimation.19 Individual lesions that scored 3-5 were first 
transperineally targeted using a 5mm-brachytherapy template grid with 2-4 cores 
taken per target. This was followed by TPM biopsies from the remainder of the 
prostate which included the targeted biopsy area. We have previously reported the 
details of how the full sampling of the prostate was conducted 14, in brief; a 5mm 
transperineal brachytherapy grid was used to take biopsies transperineally under 
general anaesthetic using TRUS guidance. If the prostate apex-base length was 
greater than the core length, two biopsies were taken at the same grid coordinate 
and labelled separately. Biopsies were taken in 20 sectors with 1-2 cores per sector 
according to the size of the prostate. (Figure 1)19  
 
Biopsy cores were analysed and reported by two dedicated expert uro-pathologists 
with over 10 years of experience in the diagnosis of prostate malignancy. Biopsy 
results were grouped into four ROIs per prostate, reflecting the mp-MRI reporting. 
Pathologists were aware of clinical details and MRI findings.  
 
Statistics 
Analysis was performed at the whole prostate level. Two-by-two and three-by-three 
tables of agreement were drawn up comparing the detection of clinically significant, 
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clinically insignificant and no cancer by each of the two-biopsy techniques. The 
primary outcome was the detection rate of clinically significant prostate cancer 
(defined using UCL/Ahmed definition 2  - Gleason ≥3+4=7 and/or maximum cancer 
core length (MCCL) ≥4mm)20. Secondary outcomes were set for a target definition of 
UCL/Ahmed definition 1 cancer only (Gleason ≥4+3=7 and/or MCCL≥6mm only, 
excluding those that met criteria of UCL/Ahmed Definition 2), any Gleason pattern 4 
or greater and ‘all cancer’. The UCL definitions were used as they were developed 
specifically and validated for the presence of 0.2cc and 0.5cc lesion on a 
transperineal sampling strategy.20 For each target condition the difference between 
the biopsy techniques was compared using McNemar’s test. Data was analysed 
using SPSS version 22 (IBM Corp 1989, 2013 Release 22.0.0.0). A p value < 0.05 
was chosen for indicating a statistically significant difference. 
 
Results 
 
Of 77 patients included, mean age was 70 years (range 61-82; SD 5.03). Median 
PSA at time of radiotherapy was 14ng/ml (range 4.5-143 IQR 7.83-32.50). 
Information on pre-radiotherapy stage and risk was available for 63 patients. Further 
baseline information is available in  Table 1.  
 
Adverse event data was available in all 77; one reported haematospermia (1.3%), 3 
(3.9%) reported dysuria with no associated infection/sepsis and 1 (1.3%) had fever 
and bowel disturbance treated with oral antibiotics for presumed gastrointestinal 
infection. 
 
 
Primary Outcome: 
Detection of Clinically Significant Cancer: Using UCL/Ahmed Definition 2, 
(Gleason>/=3+4 and/or MCCL>/=4mm), 60 (77.9%) on MRI-TB compared to 66 
(85.7%) on TPM (Table 2).   
 
In terms of agreement, 3 (3.9%) classified as clinically insignificant or no cancer on 
TPM were found to have clinically significant cancer on MRI-TB (Figures 2-4). Nine 
(11.7%) reported as having no cancer or clinically insignificant cancer on MRI-TB 
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were found to have clinically significant cancer on TPM (p=0.15) (Table 4). Eight of 
these cases were of cancer in the targeted area (targeting error) and one had cancer 
outside of the targeted area (mpMRI detection error). This patient had an overall 
mpMRI score of 3/5 in all areas of the prostate, the left posterior on TPM biopsy was 
found to be positive for Gleason 4+3 MCCL 1mm. The posterior midline was targeted 
in this patient, but this did not reveal any cancer. 
 
On a per core analysis, 190/381 (50%) of MRI-TB cores were positive for clinically 
significant cancer compared to 425/2392 (17.8%) of TPM cores. (Table 5) For the 
detection of clinically significant prostate cancer, 2.0 MRI-TB cores had to be taken 
vs. 5.6 cores on TPM biopsy (Table 5). 
 
Secondary outcomes: 
First, MRI-TB had a similar rate of detection of UCL/Ahmed Definition 1 disease 
compared to TPM (52 patients [68%] vs. 55 patients [71%]). For the detection of 
clinically significant prostate cancer 2.2 MRI-TB cores had to be taken vs. 6.3 cores 
on TPM biopsy. 
 
Second, TPM had a higher detection rate of Gleason ≥3+4 cancer compared with 
MRI-TB (65 patients [84.4%] vs. 58 patients [75.3%]). For the detection of cancer 
Gleason ≥3+4 2.1 MRI-TB cores had to be taken vs. 6.3 cores on TPM biopsy. 
 
Third, TPM had a higher all cancer detection rate 69 patients (89.6%) compared to 
63 patients (81.8%) for MRI-TB. TPM misclassified 1 patient (1.3%) as no cancer but 
found to have cancer on MRI-TB. However MRI-TB misclassified 7 patients  (9.1%) 
as no cancer that were found to have cancer on TPM biopsy. These cases were of 
cancer in the targeted area (targeting error) in 7 cases.   (p=0.07) (Table 3).  
 
Fourth, based on MRI score, 67/77 patients (87.0%) scored >/=4 (Table 6) of which 
60/67 patients (90.0%) were found to have clinically significant cancer on TPM and 
57/67 patients (85.1%) on MRI-TB (Table 7). 10/77 had an mpMRI Score of ≤3/5 Of 
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these 6/10 (60%) had clinically significant cancer on TPM (all had Gleason Score 
≥7). On MRI-TB 3/10 (30%) had clinically significant cancer (with 2 of these having 
Gleason Score ≥ 7). 
 
Discussions 
 
To our knowledge, this is the first study to compare cancer detection rates of 
transperineal MRI-targeted biopsies and transperineal template mapping biopsies in 
the radiorecurrent prostate cancer setting. We found that MRI-TB has an 
encouraging and acceptable detection rate for clinically significant prostate cancer 
using any number of definitions (68.0-77.9%). Although TPM biopsies had 10% 
higher detection rates for a more conservative definition of clinically significant 
cancer, the performance was similar for a higher threshold of disease burden. MRI-
TB was also consistently more efficient with fewer biopsies required compared with 
TPM; 1 core vs. 2.8 cores for the detection of clinically significant disease; 1.00 core 
vs. 2.9 cores for UCL/Ahmed Definition 1 disease, respectively.  
 
Limitations 
Prior to discussing the clinical implications of our findings, our study does have some 
limitations. First, the retrospective design and small sample size limits the external 
validity of our findings. We are currently recruiting to a large prospective multicentre 
study in this setting using MRI-TB versus TPM biopsies. The FORECAST (FOCal 
RECurrent Assessment and Salvage Treatment) study will incorporate the use of 
image-fusion targeted biopsies [clinicaltrials.gov number: NCT01883128]. Second, 
as nearly all of our patients were referred from external centres, there was 
incomplete information on radiotherapy doses, initial PSA and initial Gleason scores. 
Third, whilst the notion of clinically important disease is gaining acceptance in 
primary prostate cancer, such a notion has not been adequately explored in radio-
recurrent disease.  To mitigate this, we evaluated outcomes using a number of 
histological target definitions. It has been reported that delayed tumour regression 
and eventual conversion to negative biopsies occurs at a mean time of 30 months.  
21 However within our study only one patient was sampled within 30 months (at 15 
months) of completion of radiotherapy. The average time post EBRT for biopsy was 
86 months. Thus any cancer detected is likely to be a true recurrence and not a 
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continuing change in prostate tissue morphology from radiation. 
 
Comparison to existing studies 
 
Sensitivity and specificity of mpMRI have been reported as high as 86-100%12 13 22. 
However, these studies used TRUS biopsy as the reference standard so the mpMRI 
detection error may have been under reported. There is limited data available about 
the use of targeted biopsy in the radiorecurrent setting. Rud et al.23 examined the 
detection rate of DWI and MRI-US fusion targeted biopsy (MRI-US fusion TB) in men 
with radiorecurrent prostate cancer. MRI-US fusion TB had a higher rate of detection 
of cancer compared with random TRUS-guided biopsies - 83% vs 21%, respectively. 
However, poor reference standard used in this study and random biopsies were not 
performed in the area where a targeted biopsy had been undertaken. Instead 
random TRUS-guided biopsies were taken in the contralateral lobe.  
 
In order to further place our data in context of targeted biopsy series, we have to turn 
to the primary setting. There are several studies that report on the improved 
detection of cognitive MRI targeted biopsy and now MRI-US fusion targeted biopsy 
(MRI-US fusion TB) compared with whole-gland sampling in the primary setting.  
One study showed similar detection rates of MRI-TB versus TPM in primary prostate 
cancer of 57% versus 62% (p=0.174). This study also showed a higher proportion of 
cores positive for cancer with MRI-TB (38%) than with TPM (14%).24  MR-US fusion 
biopsies have reported higher cancer detection rates compared to standard 
sampling. One study compared MRI-US fusion TB with transperineal biopsy in the 
primary setting and found 46.0% of MRI-US fusion TB vs 7.5% of systematic TPM 
detected Gleason ≥7 cancers. TPM biopsy missed 20.9% Gleason ≥7 cancers 
compared to 12.8% for MRI-US fusion TB.25 A more recent study also showed that 
MRI-US fusion TB resulted in 22% and 67% additional cases of Gleason ≥3+4 and 
Gleason ≥4+3 prostate cancer than 12 core systematic biopsy, respectively.26  
 
Two recent systematic reviews have shown MRI-TB to be superior when compared 
to whole-gland transrectal systematic sampling.  Moore et al 27 examined MRI-TB 
compared with whole-gland sampling in the primary setting. Core-based analysis 
showed that just 7% of systematic cores were positive for any cancer compared to 
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30% on MRI-TB.  On a per patient basis, MRI-TB had a higher cancer detection rate 
of 48% vs. 36% for standard biopsy.  Both targeted and standard biopsy detected 
clinically significant cancer in 43% with similar rates of missing cancer (23.4% vs 
21.6%, respectively).   Another systematic review 28 reported on cancer detection 
rates of MRI-US fusion targeted biopsies in comparison to systematic biopsy. 
Clinically significant cancer was detected in 33.3% vs. 23.6%, respectively. MRI-US 
fusion biopsy was again reported to be more efficient with four times the number of 
cores needed in systematic sampling compared with an MR-US fusion TB approach. 
MRI-US fusion biopsies also detected a median of 9.1% additional clinically 
significant cancers that were missed by standard biopsy alone. Conversely, standard 
biopsies detected a median of 2.1% additional clinically significant cancers that were 
missed by MRI-US fusion TB.  It is important to note that these systematic reviews 
predominantly examined targeted biopsy in the primary setting. 
 
If our results are reproducible in further studies and larger numbers across multiple 
sites, it is possible that in future, men who fail radiation therapy and who wish to 
consider local salvage therapy should undergo a mpMRI with targeted biopsies to 
suspicious areas to confirm histological local recurrence. As with all diagnostic tests 
and strategies, a balance between accuracy and burden of the test(s) needs to be 
evaluated. The additional number of biopsy cores that are taken from TPM do lead to 
a 10% higher detection rate but in themselves are not perfect either as 
misclassification does occur. Patients and their physicians need to make an 
individualised decision weighing up the additional detection rate with the requirement 
for TPM to be carried out under general anaesthetic with high number of cores and 
side-effects that these cause. 
 
Future research needs to focus on whether image-fusion targeting has any clinical 
utility in this setting or whether mpMRI cognitive, visually directed biopsies, as we 
have carried out in our study, is sufficient. Further, mpMRI with targeted biopsy 
confirmation may facilitate greater acceptance or delivery of local salvage therapies 
such as radical prostatectomy or minimally invasive approaches such as tissue 
preserving focal salvage therapy. 4 
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Conclusions 
 
Mp-MRI targeted transperineal biopsies shows some promise in the diagnosis of 
clinically significant radiorecurrent prostate cancer when compared to a systematic 
biopsy approach using transperineal template biopsies. Further prospective multi-
centre trials are needed to determine if these results are stable and reliable across a 
larger number of men. 
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Figure 1 – Template Mapping Histopathology Report – Modified 20 Barzell 
zones 
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Table 1 - Patient baseline demographics of patients undergoing transperineal 
biopsies for suspicion of radiorecurrent prostate cancer 
 
 
Table 2 - Cancer Detection rates using TPM and MRI-TB biopsies in patients 
with radiorecurrent prostate cancer 
 TPM 
N (%) 
MRI-
TB 
N (%) 
Total 77 
(100.0) 
77 
(100.0) 
No Cancer 8 (10.4) 14 
(18.2) 
Clinical insignificant (Gleason 3+3 and </=3mm)  3 (3.9) 3 (3.9) 
UCL/Ahmed Definition 2 (Gleason>/=3+4 and/or MCCL>/=4mm) 11 
(14.3) 
8 
(10.4) 
UCL/Ahmed Definition 1 (Gleason>/=4+3 and/or MCCL>/=6mm) 55 
(71.4) 
52 
(67.5) 
 
Total No of Patients 77 
  
Mean age (range) years (SD) 70.48 (61-82) (5.03) 
  
Median PSA (ng/ml at) EBRT (range) (IQR) 14 (4.5-143 IQR 7.83-
32.5) 
  
D’Amico Risk Score at time of EBRT, N (%)  
Risk information known 63 (100) 
1 - High-risk: PSA >20, G >8, T2c-3a. 33 (52.4) 
2 - Intermediate risk: PSA 10 - 20, G7, or T2b  19 (30.2) 
3 - Low risk: PSA <10, G <6, T1-2a 11 (17.5) 
  
Time between EBRT and biochemical failure (months), 
median (range)  (IQR) 
60 (5-156 IQR 36.75-
85.00) 
  
PSA at time of MRI (ng/ml), median (range) (IQR) 4.68 (0.54-20 IQR 
2.68-7.60) 
Time between EBRT and TPM (months), median (range) 
(IQR) 
78 (15-199 IQR 61.5-
110) 
Time between mpMRI and TPM (months), median (IQR) 2.76 (1.58-4.34) 
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Table 3 – Comparison of cancer detection between TPM and MRI-TB cognitive, 
visual-estimation method in patients with radiorecurrent prostate cancer 
 
 
   TPM  
  No Cancer Any cancer Total 
MRI-TB No cancer 7 7 14 
 Any cancer 1 62 63 
 Total 8 69 77 
 
Table 4 – Comparison of clinically significant cancer detection between TPM 
and MRI-TB cognitive, visual-estimation method in patients with radiorecurrent 
prostate cancer 
 
 
   TPM  
  No Cancer/ 
Clinical 
insignificant  
cancer 
UCL/Ahmed Defn 2 OR 
UCL/Ahmed Defn 1 
Total 
MRI-TB No Cancer/ 
Clinical 
insignificant  
cancer 
8 9 17 
 UCL/Ahmed Defn 2 
OR UCL/Ahmed 
Defn 1  
3 57 60 
 Total 11 66 77 
 
 
 
Table 5 - Core based comparison of detection of any cancer, clinically 
significant cancer and cancer Gleason ≥7 between TPM and MRI-TB cognitive, 
visual-estimation method in patients with radiorecurrent prostate cancer 
 
  
TPM (%) 
 
MRI-TB (%) 
Total No of Cores 2392 (100) 380 (100) 
Any Cancer 428 (17.9) 203 (53.4) 
UCL/Ahmed Defn 2 OR UCL/Ahmed Defn 1 425 (17.8) 190 (50.0) 
Gleason Score ≥7 419 (17.5)  181 (47.6) 
UCL/Ahmed Definition 1  379 (15.8) 177 (46.6) 
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Table 6 - MRI Score and detection of any cancer, clinically significant cancer 
and Gleason >/=7 by TPM in patients with radiorecurrent prostate cancer 
 
 
MRI Score 
N 
(%) 
 
 
ANY 
CANCER
, N 
 (%) 
UCL/Ahmed Defn 2 
OR UCL/Ahmed 
Defn 1, N (%) 
 
 
GLEASON 
>/=7, N  
(%) 
 
 
UCL/Ahmed 
Defn 1, N 
 (%) 
1. Clinically 
significant 
disease is 
highly 
unlikely to 
be present 
0 (0) 
0 (0) 0 (0) 0 (0) 0 (0) 
2. Clinically 
significant 
cancer is 
unlikely to 
be present  
1 
(1.3) 
 
 
 
0 (0) 
0 (0) 0 (0) 0 (0) 
3. Clinically 
significant 
cancer is 
equivocal 
9 
(11.7) 
 
6 (66.7)  
6 (66.7) 6 (66.7) 2 (22.2) 
4. Clinically 
significant 
cancer is 
likely to be 
present 
 
25 
(32.5) 
 
 
 
22 (88.0) 
 
 
20 (80.0) 
 
 
19 (76.0) 
 
 
17 (68.0) 
5. Clinically 
significant 
cancer is 
highly likely 
to be 
present. 
42 
(54.5) 
 
 
 
41 (97.6) 
40 (95.2) 40 (95.2) 36 (85.7) 
Total 77 69 (89.6) 66 (85.7) 65 (84.4) 55 (71.4) 
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Table 7 – MRI Score and detection of any cancer, clinically significant cancer 
and Gleason >/=7 by MRI-TB cognitive, visual-estimation method in patients 
with radiorecurrent prostate cancer 
 
MRI 
Score N (%) 
 
 
ANY 
CANCER, 
N (%) 
UCL/Ahmed Defn 2 
OR UCL/Ahmed 
Defn 1, N (%) 
 
 
GLEASON 
>/=7, N 
(%) 
 
 
UCL/Ahmed 
Defn 1, N (%) 
1. 
Clinically 
significant 
disease is 
highly 
unlikely to 
be 
present 
0 (0) 
0 (0) 0 (0) 0 (0) 0 (0) 
2. 
Clinically 
significant 
cancer is 
unlikely to 
be 
present  
1 (1.3) 
0 (0) 0 (0) 0 (0) 0 (0) 
3. 
Clinically 
significant 
cancer is 
equivocal 
9 (11.7) 
3 (33.3) 3 (33.3) 2 (22.2) 2 (22.2) 
4. 
Clinically 
significant 
cancer is 
likely to 
be 
present 
25 
(32.5) 
21 (84.0) 19 (76.0) 19 (76.0) 17 (68.0) 
5. 
Clinically 
significant 
cancer is 
highly 
likely to 
be 
present. 
42 
(54.5) 
39 (92.9) 38 (90.5) 37 (88.1) 33 (78.6) 
Total 77 (100) 63 (81.8) 60 (77.9) 58 (75.3) 52 (67.5) 
 
 
 18 
Case Study  
 
 
 
Figure 2 – T2Weighted sequence MpMRI - Patient A 
 
Figure 3 –Dynamic Contrast Enhanced sequence MpMRI - Patient A 
 
Figure 4 - Histopathology Outcome – Patient A 
 
Figures 2-4 
Patient A - 72 year old patient who EBRT in 2007 for a T2c Gleason 3+3 prostate 
cancer with a presenting PSA of 16ng/ml. PSA nadir was 0.1. PSA then rising to 
2.41. MpMRI showed prostate volume 40ml and 0.4ml of likely recurrent tumour 
within the mid/basal right PZ abutting the capsule at 7 o’clock position.  There is 
small volume T2 low signal associated with restricted diffusion and focal 
enhancement - score 4/5. Patient underwent TPM and targeted biopsy. Targeted 
right PZ showed Gleason 5+4 overall in 2 of 4 cores, 2mm (15%) and 2mm (20%). 
TPM showed Gleason 3+3 in left anterior apex only. 
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